Lisata Therapeutics (LSTA) Stock Price, News & Analysis

Company Overview

Lisata Therapeutics, Inc. (NASDAQ:LSTA) is a clinical-stage biotechnology company focused on developing therapies for the treatment of cancer. The company’s research is centered on improving the delivery of anticancer agents into solid tumors and addressing the biological barriers that can limit the effectiveness of conventional cancer treatments.

Lisata’s lead investigational product is certepetide, formerly known as LSTA-1. Certepetide is a tumor-penetrating peptide designed to selectively bind to neuropilin-1, a receptor associated with tumor vasculature and the tumor microenvironment. By engaging this target, the therapy is intended to improve the penetration and distribution of concurrently administered cancer treatments within solid tumors and potentially support antitumor immune activity.

Lisata is evaluating certepetide in combination with other anticancer therapies through clinical development programs involving solid tumors, including pancreatic cancer and other difficult-to-treat malignancies. The company’s operations are focused primarily on research, development and clinical testing rather than the sale of marketed pharmaceutical products. Lisata was formerly known as Caladrius Biosciences and adopted its current name in 2021. Its corporate headquarters are in Basking Ridge, New Jersey.

Key Stats

• Today's Range: $1.26 to $1.48
• 50-Day Range: $0.99 to $1.90
• 52-Week Range: $0.99 to $5.07
• Volume: 90,754 shs
• Average Volume: 263,630 shs
• Market Capitalization: $11.35 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Reduce

Lisata Therapeutics Stock Analysis - MarketRank™

Lisata Therapeutics scored higher than 10% of companies evaluated by MarketBeat, and ranked 846th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Reduce

Consensus Rating

Lisata Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no strong buy ratings, no buy ratings, 2 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Lisata Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Lisata Therapeutics is -0.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Lisata Therapeutics is -0.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Lisata Therapeutics has a P/B Ratio of 0.76. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.02% of the float of Lisata Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Lisata Therapeutics has a short interest ratio ("days to cover") of 0.87, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lisata Therapeutics has recently increased by 16.33%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lisata Therapeutics does not currently pay a dividend.

Dividend Growth

Lisata Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 3 news articles for Lisata Therapeutics this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for LSTA on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

MarketBeat Follows

1 people have added Lisata Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Lisata Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

9.10% of the stock of Lisata Therapeutics is held by insiders.

Percentage Held by Institutions

8.94% of the stock of Lisata Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/06/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:LSTA
• CIK: 320017
• Web: www.lisata.com
• Phone: (908) 229-2590
• Fax: 646-514-7787
• Employees: 21
• Year Founded: 2006

Profitability

• EPS (Trailing Twelve Months): ($1.64)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$16.59 million
• Net Margins: N/A
• Pretax Margin: -15,008.00%
• Return on Equity: -116.08%
• Return on Assets: -90.55%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.69
• Quick Ratio: 3.69

Sales & Book Value

• Annual Sales: $170 thousand
• Price / Sales: 66.78
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.66 per share
• Price / Book: 0.76

Miscellaneous

• Outstanding Shares: 9,010,000
• Free Float: 8,191,000
• Market Cap: $11.35 million
• Optionable: Not Optionable
• Beta: 0.94